Clinical Trial Update: Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR) [Phase 2, Phase 3]

View source ↗

Summary

A pediatric safety, efficacy, and pharmacokinetic study of Allegra (fexofenadine) in children with perennial allergic rhinitis has completed Phase 2/3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• Allegra (fexofenadine)

Snippet

Sponsor: Sanofi | Conditions: Rhinitis Perennial | Phase 2, Phase 3 | Status: COMPLETED